518th Edition, July 26, 2022

Trouble Viewing This Email: Click Here

July 26, 2022

FOUNDING MEMBER OF

BHI Seeks Senior Life Sciences Business Strategist – Apply Now!

Currently reporting to the Vice President of Economic Development, the Senior Life Sciences BusinessCurrently reporting to the Vice President of Economic Development, the Senior Life Sciences BusinessStrategist evaluates the commercial potential of emerging technologies and provides recommendations ongo-to-market strategies.

Deka Biosciences Breaks Ground on New Facility

GERMANTOWN, Md., July 19, 2022 /PRNewswire/ — Deka Biosciences announced today that it is breaking ground on a 14,000 square foot office and lab which will house a state of the art Research and Development, Process Development, and Manufacturing facility to further develop their novel cytokine therapies. This will be the first facility to house a dual targeted cytokine development lab in the DC/Maryland/Virginia region and the only company in the US developing a therapeutic of its kind. The new headquarters will be located at 20380 Seneca Meadows Parkway in Germantown, Maryland and Deka anticipates the move to be completed in the first quarter of 2023.

Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma

ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced dosing of the first patient in the company’s Phase 1 study evaluating ITI-3000, a plasmid DNA (pDNA) vaccine targeting patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer that is typically caused by the Merkel cell polyomavirus (MCPyV). The single-center study is being conducted at the University of Washington School of Medicine and the Fred Hutchinson Cancer Center in Seattle, Washington and is being led by Drs. Paul Nghiem, Song Park and David M. Koelle.

Polaris Genomics Announces Continued Research & $100K Grant Awarded from Maryland Industrial Partnership Program (MIPS) – EIN Presswire

ROCKVILLE, MD, UNITED STATES, July 19, 2022 /EINPresswire.com/ — The biotech startup that brought to light the first and only PTSD genomic test announces continued research and innovation with continued funding from a second $100,000 matching grant awarded by the Maryland Industrial Partnership Program (MIPS).

In the Fall of 2020, Polaris Genomics was awarded a $100,000 matching grant by MIPS and began partnering with researchers at the University of Maryland Baltimore to test the performance of PTS-ID, a genomic blood test to identify persons with PTSD, measure disease severity and detect treatment response.

Children’s National Hospital gets federal funding for pandemic preparedness – Washington Business Journal

The grant focuses on a few areas across four years, including addressing health disparities.

Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes

GAITHERSBURG, Md., July 19, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, has signed agreements with its partner, SK bioscience, for the manufacturing and supply of a version of the Novavax COVID-19 vaccine (NVX-CoV2373) containing Omicron variant and for the manufacture of the vaccine in prefilled syringes.

The companies signed an agreement for the technology transfer of Novavax' proprietary COVID-19 variant antigen materials so that SK bioscience can manufacture the drug substance targeting COVID-19 variants including the Omicron BA.5 subvariant.

Maryland Inno – Baltimore startup Delfi Diagnostics raises $225M with plans to change how lung cancer is diagnosed

Baltimore biotechnology startup Delfi Diagnostics has raised $225 million as it embarks on a 15,000-person trial for its early cancer detection technology.

The oversubscribed Series B round was the second mega-deal of the year in Greater Baltimore. DFJ Growth led the round, with participation from local Baltimore institutions such as T. Rowe Price Associates, Brown Advisory, PTX Capital and Rock Springs CapitalNational institutions such as Eli Lilly and Co., Point 72, Menlo Ventures and others also participated. The company previously raised $100 million in a Series A round in January 2021, and all of Delfi's previous investors also joined in the Series B round. Delfi began the fundraise in early 2022 and closed in July.

Image: Delfi Diagnostics, led by founder and CEO Victor Velculescu closed a $225 million series B round. Julien Capmeil

Maryland Inno – Maryland sees an increase in VC dollars in Q2 despite a national decline

Maryland bucked a national trend in venture capital funding in the second quarter of 2022, recording an increase in the number of companies able to raise money even as the rest of the nation continued to struggle with the declining markets.

Nationally, VC deals decreased massively from $341.5 billion in the first quarter of 2022 to $144.2 billion in the second quarter. Maryland trended in the opposite direction seeing a massive increase in VC funding this quarter compared to the beginning of the year. In the first quarter, Maryland companies saw $325 million in funding, and in the second quarter that number more than doubled to $747.95 million.

Construction Continues at Progress Labs in Gaithersburg – The MoCo Show

Progress Labs at Progress Way in Gaithersburg, MD is a two-building approximately 495,000 SF development situated on 44 acres with I-270 visibility and access off of exit 11 Montgomery Village Avenue. Construction commenced at Progress Labs at 700 N. Frederick Avenue in Gaithersburg, MD back in October, and according to the video below (posted by Progress Labs on Monday, July 18th), is scheduled to be delivered in Q4 of 2022, which is ahead of schedule based on the schedule provided on its website, also seen below:

Building 1 Early TI Start: 11/2022

Building 2 Early TI Start: 2/2023

Building 1 Base Building Substantial Completion: 1/2023

Building 2 Base Building Substantial Completion: 4/2023

Novavax, advancing COVID-19 shot, recruits AstraZeneca exec as its chief medical officer | Fierce Pharma

On the heels of some big fundraising moves and in the hunt for a COVID-19 vaccine, Novavax is adding some Big Pharma experience to its executive team.

Joining the company's leadership team as chief medical officer is Filip Dubovsky, an AstraZeneca veteran. Dubovsky joins Novavax directly from the British drugmaker, where he served as head of clinical engagement and policy, plus as chief medical officer for clinical affairs. Before that role, he oversaw a portfolio of more than two dozen malaria vaccines at the PATH Malaria Vaccine Initiative.

Image: ovavax recruited two pharma and biotech veterans to senior posts. (Novavax)

Omicron subvariants and the changing landscape of COVID-19 | Hub

Omicron is mutating in giant leaps, with scientists racing to keep up. Its diversity is challenging vaccine efficacy and complicating treatment. But this fall, broad spectrum bivalent vaccines may help mitigate the seemingly never-ending spread of COVID-19.

Johns Hopkins virologist Andy Pekosz has been tracking coronavirus variants since the early days of the pandemic. He recently spoke to the Public Health On Call podcast about the range of omicron subvariants, omicron-specific vaccines, and what we can expect to see in the future from this "game-changer" variant.

Viewport
Window
×
×
×

Leave a Reply Cancel Reply

About BioHealth Innovation

Contact

Connect